BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Credit Suisse upgrades Sun Pharma to outperform
Company has taken price increase across branded portfolio. It has also increased price across portfolios of Ranbaxy and Dusa. Raise our FY17 and FY18 earnings per share estimates by 2 and 4 per cent respectively.